AnaptysBio abandons eczema drug after trial failures; shares nosedive
Biotechnology company AnaptysBio, Inc., specializing in innovative autoimmune disease therapies, announced it will halt development of its atopic dermatitis treatment, ANB032, after the drug failed ... Read More
Rallybio Phase 2 trial of RLYB212 begins to tackle FNAIT in high-risk pregnancies
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company known for advancing innovative therapies for rare diseases, has commenced its Phase 2 clinical trial for RLYB212. ... Read More
Revolutionary anti-aging drug sends Telomir Pharma stock soaring—Is the future of longevity here?
Shares of Telomir Pharmaceuticals, Inc. rose significantly in after-hours trading on Wednesday, regaining lost ground following a promising update about its anti-aging drug, Telomir-1. After ... Read More
Coya Therapeutics stock surges as investors pump $10m into growth
Coya Therapeutics Inc. (NASDAQ: COYA) witnessed a 9% increase in its share value after securing $10 million through a private placement. The biotechnology firm, specializing ... Read More
Actinogen Medical makes bold A$11.1m move to boost Alzheimer’s drug trial
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven Gourlay, who personally invested 1 million AUD. ... Read More
FDA extends review period for Humacyte’s vascular trauma treatment ATEV
The U.S. Food and Drug Administration’s review of Humacyte, Inc.'s innovative vascular trauma treatment, known as the acellular tissue engineered vessel (ATEV), has hit an ... Read More
Recursion Pharmaceuticals and Exscientia announce merger to transform drug development
Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have announced a landmark merger, combining their strengths to form a formidable entity in drug ... Read More
AbbVie acquires Celsius Therapeutics to enhance inflammatory disease treatment options
In a significant move within the biotechnology industry, AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, has completed the acquisition of Celsius Therapeutics, Inc., a ... Read More
MediLink Therapeutics, BioNTech expand partnership with new $1.8bn agreement
MediLink Therapeutics (Suzhou) Co., Ltd., a prominent clinical-stage biotech company, has entered into a significant new strategic collaboration with BioNTech SE, a leader in next-generation ... Read More
Innovent Biologics reports significant clinical success with picankibart in psoriasis treatment
Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its novel drug, picankibart (R & D code: ... Read More